Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens [Hematologic Malignancy]
Conclusion
Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Niesvizky, Flinn, Rifkin, Gabrail, Charu, Clowney, Essell, Gaffar, Warr, Neuwirth, Zhu, Elliott, Esseltine, Niculescu, Reeves Tags: Geriatric Oncology, Translational Oncology Hematologic Malignancy Source Type: research
More News: Cancer & Oncology | Dexamethasone | Geriatrics | Hematology | Myeloma | Prednisone | Toxicology | Transplants | Velcade